

# Group at a Glance

## EU Pharmaceuticals

### Dechra Veterinary Products EU (DVP EU)



**364**  
Employees



**14**  
Countries

DVP EU markets and sells Dechra's products throughout Europe and exports to over 40 countries. The business has an operating board of eight senior managers, and is managed from Den Bosch, the Netherlands, Sansaw, UK, and Uldum, Denmark. In total, DVP EU employs 364 people and maintains an outsourced sales force of 20 people located in different territories. Inventory is managed through a central distribution centre in Uldum, Denmark.

DVP EU has sales operations in 14 countries: Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the UK, each run by a Country Manager. DVP EU also exports to other European countries as well as other territories including Australia, Brazil, the Middle East and the Far East.

The key products in the DVP EU portfolio are predominantly Companion Animal and Equine Products; however, with the acquisition of *Eurovet*® in 2012, the range expanded into the food producing animal market.

DVP EU also markets a range of specialist, therapeutic and maintenance pet diets, branded *Specific*™.

### Dechra Pharmaceuticals Manufacturing (DPM)



**374**  
Employees



**3**  
Manufacturing Sites

DPM produces the majority of Dechra's pharmaceuticals and also manufactures for third parties on a contract basis. The objectives of manufacturing are to produce Dechra's veterinary pharmaceutical product range efficiently and economically to the highest quality standards, maintain a robust and reliable supply chain for the Group and to contribute revenue and profit to the business through third party manufacturing.

#### Skipton

The site at Skipton, UK, employs 239 people, and offers a comprehensive range of pharmaceutical manufacturing and packing services, principally for Companion Animal Products (CAP). The site is dual-licensed to produce both veterinary and human products. The site includes Pharmaceutical Development, Quality Control (QC) and Stability Testing and Validation Laboratories.


#### Bladel

The site at Bladel, the Netherlands, employs 122 people. The operation complements the Skipton site, manufacturing products for food producing animals in large-scale batches. This site also has an aseptic manufacturing facility to produce sterile injections, an important competence in DPM's manufacturing portfolio. As in Skipton, the site includes QC and Development Laboratories.


#### Melbourne

The site at Melbourne, Florida, employs 13 people. It manufactures *Phycox* and *Levocrine*®.


### Revenue for the EU Pharmaceuticals Segment



### Profit Evolution for EU



### Manufacturing Volumes



All figures are at AER.

[www.dechra.com](http://www.dechra.com)